MX2010011672A - Conjugados del factor ix con vidas medias extendidas. - Google Patents

Conjugados del factor ix con vidas medias extendidas.

Info

Publication number
MX2010011672A
MX2010011672A MX2010011672A MX2010011672A MX2010011672A MX 2010011672 A MX2010011672 A MX 2010011672A MX 2010011672 A MX2010011672 A MX 2010011672A MX 2010011672 A MX2010011672 A MX 2010011672A MX 2010011672 A MX2010011672 A MX 2010011672A
Authority
MX
Mexico
Prior art keywords
factor
conjugates
lives
extended half
contamination
Prior art date
Application number
MX2010011672A
Other languages
English (en)
Inventor
Henry William
Original Assignee
Celtic Pharma Peg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtic Pharma Peg Ltd filed Critical Celtic Pharma Peg Ltd
Publication of MX2010011672A publication Critical patent/MX2010011672A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a conjugados del Factor IX que han sido modificados para incluir una porción del polímero biocompatible. Los conjugados del Factor IX están sustancialmente libres de contaminación por el Factor IXa. Los conjugados del Factor IX tienen propiedades farmacocinéticas mejoradas, tales como vida media incrementada, lo cual da como resultado dosis moderada y administración menos frecuente.
MX2010011672A 2008-04-24 2009-04-24 Conjugados del factor ix con vidas medias extendidas. MX2010011672A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4754408P 2008-04-24 2008-04-24
PCT/IB2009/005763 WO2009130602A2 (en) 2008-04-24 2009-04-24 Factor ix conjugates with extended half-lives

Publications (1)

Publication Number Publication Date
MX2010011672A true MX2010011672A (es) 2011-03-02

Family

ID=41171051

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011672A MX2010011672A (es) 2008-04-24 2009-04-24 Conjugados del factor ix con vidas medias extendidas.

Country Status (23)

Country Link
US (1) US20110183906A1 (es)
EP (1) EP2280734B1 (es)
JP (1) JP2011519833A (es)
KR (1) KR20110016440A (es)
CN (1) CN102046205A (es)
AU (1) AU2009239641B2 (es)
BR (1) BRPI0911350A2 (es)
CA (1) CA2722169A1 (es)
CO (1) CO6300965A2 (es)
CR (1) CR11763A (es)
DK (1) DK2280734T3 (es)
EC (1) ECSP10010632A (es)
ES (1) ES2466340T3 (es)
HK (1) HK1151986A1 (es)
IL (1) IL208908A0 (es)
MX (1) MX2010011672A (es)
MY (1) MY158228A (es)
NI (1) NI201000177A (es)
NZ (1) NZ588854A (es)
RU (1) RU2496521C2 (es)
UA (1) UA101497C2 (es)
WO (1) WO2009130602A2 (es)
ZA (1) ZA201007559B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
US20120148557A1 (en) * 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
GB201007356D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
AU2012262428C1 (en) * 2011-05-27 2018-10-11 Takeda Pharmaceutical Company Limited Therapeutic proteins with increased half-life and methods of preparing same
GB2516388A (en) * 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
BR112014031613A2 (pt) * 2012-06-19 2017-07-25 Polytherics Ltd processo para preparação de conjugados de anticorpos e conjugados de anticorpos
TWI810729B (zh) 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
GB2564389A (en) 2017-07-04 2019-01-16 Green Running Ltd A system and method for utility management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
RU2278123C2 (ru) * 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
WO2004060965A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
ES2308032T5 (es) * 2002-12-31 2017-04-24 Nektar Therapeutics Derivados poliméricos de ácido maleámico y sus bioconjugados
KR101207247B1 (ko) * 2003-01-06 2012-12-03 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ｉｘ因子調製物およびその精製方法
EP2189523B1 (en) 2003-10-14 2012-01-04 Baxter International Inc. Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
WO2006063292A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
JP2008531026A (ja) 2005-02-28 2008-08-14 バクスター・インターナショナル・インコーポレイテッド ビタミンｋ依存性タンパク質発現を改善するための、ビタミンｋエポキシドレダクダーゼサブユニット１の組換え同時発現
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
EP2975135A1 (en) * 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
US20090252720A1 (en) * 2006-05-24 2009-10-08 Novo Nordisk Health Care Ag Prolonged FIX Analogues and Derivatives
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病ｂ治療剤及びその製造方法

Also Published As

Publication number Publication date
IL208908A0 (en) 2011-01-31
AU2009239641A1 (en) 2009-10-29
UA101497C2 (ru) 2013-04-10
ECSP10010632A (es) 2011-02-28
JP2011519833A (ja) 2011-07-14
ZA201007559B (en) 2012-01-25
NZ588854A (en) 2011-12-22
CO6300965A2 (es) 2011-07-21
HK1151986A1 (en) 2012-02-17
RU2010147813A (ru) 2012-05-27
CR11763A (es) 2011-04-26
EP2280734B1 (en) 2014-02-26
RU2496521C2 (ru) 2013-10-27
CA2722169A1 (en) 2009-10-29
EP2280734A2 (en) 2011-02-09
WO2009130602A2 (en) 2009-10-29
ES2466340T3 (es) 2014-06-10
DK2280734T3 (da) 2014-05-26
AU2009239641B2 (en) 2013-11-07
US20110183906A1 (en) 2011-07-28
CN102046205A (zh) 2011-05-04
MY158228A (en) 2016-09-15
BRPI0911350A2 (pt) 2017-12-05
WO2009130602A9 (en) 2010-04-22
KR20110016440A (ko) 2011-02-17
NI201000177A (es) 2011-08-29
WO2009130602A3 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
MY158228A (en) Factor ix conjugates with extended half-lives
MY158890A (en) Pegylated insulin lispro compounds
MX344009B (es) Conjugados de amatoxinas con enlaces mejorados.
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
MX344010B (es) Conjugados de amatoxina con enlazantes mejorados.
NZ599880A (en) Use of bethanechol for treatment of xerostomia
MX356826B (es) Conjugados de molecula pequeña para suministro intracelular de compuestos biologicamente activos.
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
MX350539B (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
HK1148202A1 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
EA032867B9 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
MX2011003738A (es) Conjugados hpma-docetaxel o gemcitabine y sus usos asociados.
JO3026B1 (ar) مستضادات ببتيد شبيه الجلوكاجون - 2
NZ610526A (en) Deuterium enriched rasagiline
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
PH12017502392A1 (en) Targeted conjugates and particles and formulations thereof
WO2011054837A3 (de) Bifunktionale prodrugs und drugs
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
MD20140123A2 (ro) Agenţi terapeutici optimizaţi pentru administrare subcutanată
PH12014502571A1 (en) Ophthalmic compositions with improved dessication protection and retention
UA106876C2 (uk) (полі)аміноалкіламіноалкіламідні, алкілсечовинні або алкілсульфонамідні похідні епіподофілотоксину, спосіб їх одержання та їх застосування в терапії як протиракових засобів
WO2009027844A3 (en) Crf conjugates with extended half-lives
MX347677B (es) Formulacion farmaceutica entre jasmonatos y sus derivados y nanoportadores o microportadores.
MX2012003230A (es) Composiciones farmaceuticas de rapamicina.
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED.*

FG Grant or registration